Vadadustat

Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor[1]. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo[1][2].

Product Specifications

CAS Number

[1000025-07-9]

Product Name Alternative

PG-1016548; AKB-6548

UNSPSC

12352005

Hazard Statement

H303, H320

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Vadadustat.html

Concentration

10mM

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CNC(C1=NC=C(C2=CC=CC(Cl)=C2)C=C1O)=O

Molecular Formula

C14H11ClN2O4

Molecular Weight

306.70

Precautions

H303, H320

References & Citations

[1]Pergola PE, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90 (5) :1115-1122.|[2]Gupta N, et al. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Feb 24. pii: S0272-6386 (17) 30110-5.